NTLA
Pipeline first, profits later
Intellia’s second-quarter update was basically a biotech version of “don’t look at the mess in the kitchen, look at the soufflé.” The company said its Phase 3 programs for LVOSI in hereditary angioedema and Nexi in transthyretin amyloidosis kept moving, with LVOSI posting an 87% drop in mean monthly attacks in the Halo trial and setting up a potential FDA approval and U.S. launch in the first half of next year.
The part investors actually care about
That’s the good stuff: clinical momentum plus a clearer path to commercialization. Intellia also said it’s already doing the pre-launch homework — payer outreach, medical engagement, and all the unglamorous work that matters when you’re trying to turn a science project into an actual business.
Meanwhile, Nexi got some breathing room after clinical holds were resolved and enrollment resumed. The company flagged an HLA allele linked to higher liver transaminase elevations, and said updated protocols are being used to manage it. Translation: there’s still risk, but the plot holes are being patched rather than ignored.
Cash helps keep the lights on
On the money side, Intellia raised $195 million in equity financing and ended the quarter with $628.4 million in cash, which it says should fund operations into 2028, excluding any product revenue. It posted a net loss of $106.6 million, but for a biotech like this, the runway is often the story before the earnings are.
Big picture: Intellia is trying to turn a pair of promising gene-editing programs into a real commercial story, and this quarter suggests the roadmap is getting a little less sci-fi and a little more concrete.